Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis-Reference-Cited by-同舟云学术

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

Published:2014-07 Issue:9938 Volume:384 Page:164-172
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Cortazar Patricia,Zhang Lijun,Untch Michael,Mehta Keyur,Costantino Joseph P,Wolmark Norman,Bonnefoi Hervé,Cameron David,Gianni Luca,Valagussa Pinuccia,Swain Sandra M,Prowell Tatiana,Loibl Sibylle,Wickerham D Lawrence,Bogaerts Jan,Baselga Jose,Perou Charles,Blumenthal Gideon,Blohmer Jens,Mamounas Eleftherios P,Bergh Jonas,Semiglazov Vladimir,Justice Robert,Eidtmann Holger,Paik Soonmyung,Piccart Martine,Sridhara Rajeshwari,Fasching Peter A,Slaets Leen,Tang Shenghui,Gerber Bernd,Geyer Charles E,Pazdur Richard,Ditsch Nina,Rastogi Priya,Eiermann Wolfgang,von Minckwitz Gunter

Publisher

Elsevier BV

Subject

General Medicine

Reference27 articles.

1. Pathological complete response and accelerated drug approval in early breast cancer;Prowell;N Engl J Med,2012

2. Preoperative chemotherapy in operable breast cancer;Bonadonna;Lancet,1993

3. Primary systemic therapy for operable breast cancer—10-year survival data after chemotherapy and hormone therapy;Cameron;Br J Cancer,1997

4. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer;Liedtke;J Clin Oncol,2008

5. Preoperative chemotherapy for women with operable breast cancer;Mieog;Cochrane Database Syst Rev,2007

Cited by 3313 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Additional statin treatment enhances the efficacy of HER2 blockade and improves prognosis in Rac1-high/HER2-positive breast cancer;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2024-12

2. Major pathologic response and long-term clinical benefit in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer after neoadjuvant chemotherapy;The Breast;2024-12

3. Clinical applications of radiomics and deep learning in breast and lung cancer: A narrative literature review on current evidence and future perspectives;Critical Reviews in Oncology/Hematology;2024-11

4. A multidisciplinary team and patient perspective on omission of surgery after neoadjuvant systemic therapy for early breast cancer: A European Society of Surgical Oncology (ESSO) Research Academy survey;European Journal of Surgical Oncology;2024-10

5. Implications of nanotherapeutic advancements to leverage multi-drug resistant breast cancer: The state-of-the-art review;Journal of Drug Delivery Science and Technology;2024-10